Is bevacizumab covered by medical insurance?

Bevacizumab (Bevacizumab) is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Its mechanism is mainly to inhibit the formation of new blood vessels in tumors, thereby inhibiting the growth and spread of tumors.

As one of the most widely used anti-angiogenic drugs in the world, bevacizumab has been recommended by authoritative guidelines in many countries and regions for the treatment of various malignant solid tumors. Its indications are mainly concentrated in the field of tumor diseases, covering non-small cell lung cancer, metastatic colorectal cancer, advanced ovarian cancer, cervical cancer, renal cell carcinoma, hepatocellular carcinoma, recurrent glioblastoma, etc.

There are differences in dosage regimens, treatment courses and dosages for different indications. It is usually used in combination with other chemotherapy or immunological drugs under the guidance of a physician to enhance the efficacy and delay disease progression. Especially in advanced or relapsed cases, bevacizumab is often used as maintenance therapy or second-line treatment, showing certain advantages in improving progression-free survival.

In China, bevacizumab has been approved by the State Food and Drug Administration for many years and has been officially included in the National Medical Insurance Drug List after multiple rounds of national medical insurance negotiations. According to the latest medical insurance policy, multiple indications of this drug are included in the scope of reimbursement. The diseases covered include advanced non-small cell lung cancer, metastatic colorectal cancer, liver cancer, cervical cancer, ovarian cancer, etc. The medical insurance reimbursement standards cover most common clinical drug scenarios.

It should be pointed out in particular that medical insurance payment usually has preconditions, including diagnosis criteria, whether the treatment plan is consistent with the guidelines, and whether the medication cycle is within the limits of medical insurance, etc. In addition, most of the drugs included in the medical insurance catalog are bid-winning products, including some domestic biosimilar drugs. These drugs have a price advantage compared with the original drugs, and have passed bioequivalence verification in terms of efficacy, and are gradually being widely used in clinical practice. When patients choose specific drugs, they can comprehensively consider them based on doctor's recommendations and medical insurance reimbursement status.

Reference materials:https://www.drugs.com/bevacizumab.html